Ventyx Biosciences, Inc. Class Action Lawsuit - VTYX

The filed complaint alleges that Ventyx Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) VTX958, the Company's lead clinical product candidate, was less effective in treating psoriasis than defendants had led investors to believe; (ii) as a result, VTX958’s clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx’s business prospects following the initial public offering were thus inflated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the VTYX class action lawsuit, you must have incurred a loss on shares of Ventyx purchased during the class period listed above.

If you suffered a loss in Ventyx during the relevant time frame or pursuant to the relevant offering(s), you have until April 30, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.